FDA supplemental approval: Morphine Sulfate (REMS)

AI Summary

This is an FDA supplemental approval record for a REMS (Risk Evaluation and Mitigation Strategy) for morphine sulfate extended-release tablets in four strengths (30 mg, 60 mg, 100 mg, 200 mg), approved on 18 June 2026 by SUN PHARMA INDUSTRIES. The record itself contains no clinical trial results, efficacy data, or safety comparative evidence.

Plain-language summary

FDA supplemental approval of a Risk Evaluation and Mitigation Strategy (REMS) for morphine sulfate extended-release tablets; this is a regulatory action, not a clinical trial, and does not report efficacy or safety trial data.

Reported figures

Quoted from the source exactly as published.

Clinical bottom line

This regulatory action pertains to the risk mitigation requirements (REMS) for morphine sulfate extended-release products. Clinicians and dispensers should ensure compliance with the applicable REMS program requirements; however, this record does not provide efficacy, safety, or comparative effectiveness data to inform clinical decision-making.

Caveats

• This is a regulatory filing record and contains no clinical trial results, safety data, or efficacy comparisons.
• The specific REMS requirements and their rationale are not detailed in this record.
• No information on prior approvals, modifications to labeling, or new safety signals is provided.
• No information on intended use population or clinical indications is stated beyond product formulations.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.